[9] Consequently, a group of pulmonary hypertension specialists initiated a voluntary collaborative survey entitled Surveillance of North American Pulmonary Hypertension (SNAP). The goal of the ...

Pulmonary hypertension is classified into 5 groups based on its cause, according to the American Lung Association: This group includes idiopathic PAH, heritable PAH (due to genetic factors), and ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart ... with the remaining 3 patients currently completing Part ...

Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair ... for the treatment of adults with pulmonary arterial hypertension PAH WHO Group 1 to increase exercise capacity, improve ...

F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ... with the remaining 3 patients currently completing ...